Transcranial Photobiomodulation With Patients With Parkinson's Disease

Al-Zaytoonah University of Jordan38 enrolled

Overview

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is a progressive and disabling disease with significative impact on quality of life. Since it has no cure, available treatment is targeted to improve the symptoms due to a lack of dopamine in the central nervous system. The aim of the study was to see how transcranial photobiomodulation (tPBM) helped patients with Parkinson's disease.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Parkinson Disease

Interventions

transcranial photobiomodulationDEVICE

Single-session transcranial laser stimulation was administered with a continuous-wave, 1,064-nm laser (Model CG-5000 Laser, Cell Gen Therapeutics LLC, Dallas, TX).

exercises trainingOTHER

balance exercises and others

Eligibility

Sex: ALLMin age: 50 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * idiopathic PD, * Hoehn \& Yahr stage I-IV, * independent gait with or without technical assistance * stable parkinsonian medication for at least a month before the study star. Exclusion Criteria: * comorbidities that affect balance or walking, * other neurological pathologies besides PD, * chronic diseases not medically controlled and participation in another physiotherapy program or sport activity during the intervention period or in the month before starting the study

Locations (1)

Al Zaytoonah University

Amaan, Jordan

Outcomes

Primary Outcomes

posture stability

The Biodex Balance System (Biodex Medical Systems Inc, USA) Will be used to assess the limit of stability (overall, forward and backward) pre- and post-treatment.

Time frame: 8 weeks

Secondary Outcomes

functional activity

The modified Parkinson activity scale (mPAS) consist of 14 items arranged on to three domains: chair transfer (2 items), gait akinesia (6 items) and bed mobility (6 items)

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.